HR+/HER2- Advanced Breast Cancer: Chemotherapy-Free Options For Various Subgroups

by Jens Huober | 13 September 2024 | Women's Cancers

A diverse therapeutic landscape is now available for managing HR-positive/HER2-negative advanced breast cancer. A broad spectrum of patients can be covered with targeted approaches in addition to endocrine therapy. The PALOMA-2, MONALEESA-2, and MONARCH 3 studies have...

Early Breast Cancer: New Findings Through Subgroup And Biomarker Analyses

by Konstantin Dedes | 5 September 2024 | Women's Cancers

Study data presented at the 2024 ASCO Congress demonstrate that CDK4/6 inhibitors and other therapies are effective in treating early breast cancer within specific subgroups. New biomarker data can also refine treatment algorithms. In patients with hormone receptor...

HER2 As A Target For Gastrointestinal Tumors

by Florian Lordick | 21 August 2024 | Gastrointestinal

Clinically relevant HER2 expression is found in some gastrointestinal tumors, such as carcinomas of the stomach and colon, which makes therapeutic targeting with proven and new substances possible. In the group of predictive markers evaluated in gastric cancer and...

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...

Metastatic Prostate Cancer: Optimization of Systemic Treatment

by Deborah Mukherji | 3 July 2024 | Urogenital

Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and...